Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.30 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
| ▸ | ITGAV | P06756 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.30 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.30 |
| ▸ | ITGAL | P20701 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1061581 | 1.00 | CRBN (0.36) | CRBNMAP3K14ITGB3ITGB2ITGB1 | |
| SCHEMBL9036073 | 0.83 | — | — | |
| SCHEMBL4976776 | 0.83 | — | — | |
| SCHEMBL14028662 | 0.76 | CRBN (0.39) | CRBNMAP3K14TSHR | |
| SCHEMBL5433985 | 0.71 | — | — | |
| SCHEMBL4756282 | 0.68 | ITGB1 (0.39) | CRBNMAP3K14ITGB3ITGB2ITGB1 | |
| SCHEMBL8285795 | 0.67 | — | — | |
| SCHEMBL13033027 | 0.67 | — | — | |
| SCHEMBL21731425 | 0.67 | — | — | |
| SCHEMBL1774204 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150079179-A1 | SUSTAINED RELEASE FORMULATIONS OF PEPTIDOMIMETIC DRUGS AND USES THEREOF | JERINI OPHTHALMIC INC (US) | 2015-03-19 | — | — | US | disclosed |
| US-20120244192-A1 | SUSTAINED RELEASE FORMULATIONS OF PEPTIDOMIMETIC DRUGS AND USES THEREOF | JERINI OPHTHALMIC INC. | 2012-09-27 | — | — | US | disclosed |
| EP-2424556-A1 | SUSTAINED RELEASE FORMULATIONS OF PEPTIDOMIMETIC DRUGS AND USES THEREOF | Jerini Ophthalmic Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110003756-A1 | C5a Receptor Antagonists | JERINI AG (DE) | 2011-01-06 | — | — | US | disclosed |
| WO-2010126833-A1 | SUSTAINED RELEASE FORMULATIONS OF PEPTIDOMIMETIC DRUGS AND USES THEREOF | JERINI OPHTHALMIC INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-7727960-B2 | C5a receptor antagonists | JERINI AG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20060183883-A1 | C5a Receptor antagonists | JERINI AG (DE) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183883-A1 | C5a Receptor antagonists | C5AR1, C3AR1, C5AR2 | CRBN 721/4885MAP3K14 4294/4885ITGB3 623/4885 |
| US-20110003756-A1 | C5a Receptor Antagonists | C5AR1, C3AR1, C5AR2 | CRBN 905/4885MAP3K14 4048/4885ITGB3 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.